Chemours (CC)
(Delayed Data from NYSE)
$19.44 USD
+0.10 (0.52%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $19.44 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.44 USD
+0.10 (0.52%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $19.44 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value F Growth D Momentum F VGM
Zacks News
Chemours (CC) Opens Cutting-Edge Facility for EV Batteries
by Zacks Equity Research
Chemours (CC) opens the Chemours Battery Innovation Center to advance sustainable battery technology for electric vehicles.
Chemours (CC) Earnings Miss, Revenues Beat Estimates in Q2
by Zacks Equity Research
Chemours' (CC) earnings miss estimates in the second quarter due to lower selling prices.
Chemours (CC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Misses Q2 Earnings Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of -42.42% and 0.01%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can These 4 Chemical Stocks Hit Targets This Earnings Season?
by Anindya Barman
Chemical companies are expected to have benefited from demand recovery across key end markets and moderated de-stocking activities. Let's see how APD, CE, CC and AXTA are poised ahead of their earnings releases.
Do Options Traders Know Something About Chemours (CC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.
Analysts Estimate LyondellBasell (LYB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
LyondellBasell (LYB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Chemours (CC) Q2 Earnings Expected to Decline
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) Soars 5.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Chemours (CC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Chemours (CC) Announces Enhancement of EVOLVE 2030 Methodology
by Zacks Equity Research
The revised EVOLVE 2030 approach improves Chemours' (CC) ability to integrate its business processes with this goal.
Why Is Chemours (CC) Down 2.1% Since Last Earnings Report?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours (CC) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
Lower volumes and prices hurt Chemours' (CC) top line in the first quarter.
Chemours (CC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 28% and 0.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Chemours (CC) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stepan Co. (SCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Stepan Co. (SCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Chemours (CC) Just Reclaimed the 50-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
Company News for Apr 1, 2024
by Zacks Equity Research
Companies In The News Are: RH, AMC, CC, WBA.
Chemours (CC) Q4 Earnings Beat, Revenue Miss Estimates
by Zacks Equity Research
Chemours (CC) fourth-quarter earnings beat estimates, while sales miss despite growth across TT and TSS segments.
Chemours (CC) Q4 Earnings Top Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 6.90% and 0.69%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Chemours (CC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Chemours (CC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Eastman Chemical (EMN) Gains on Cost Cuts and Innovation
by Zacks Equity Research
Eastman Chemical (EMN) benefits from cost-management actions and innovation amid challenges from soft demand and consumer de-stocking in certain markets.